Ulcerative Colitis
Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Inflammatory Bowel Disease (IBD), TL1A Antibody, Duvakitug, Crohn’s Disease, Ulcerative Colitis, Precision Medicine, Immunology, Gastrointestinal Diseases
FDA Approves TREMFYA (Guselkumab) for Moderately to Severely Active Ulcerative Colitis
TREMFYA, Guselkumab, FDA Approval, Ulcerative Colitis, Inflammatory Bowel Disease, Johnson & Johnson
Johnson & Johnson’s TREMFYA Receives FDA Approval for Ulcerative Colitis, Expanding Treatment Options
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson